Ariane Kronthaler

Ms. Ariane Kronthaler

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in Surfaces
Verified
Journal Article
Open access
PDF file
ARAnna Maria Reider
Anna Maria Reider
AKAriane Kronthaler
Ariane Kronthaler
FZFabio Zappa
Fabio Zappa
AMAlexander Menzel
Alexander Menzel
FLFelix Laimer
Felix Laimer
PSP. Scheier
P. Scheier
Titanium thin films with thicknesses of up to 105 nm were deposited on borosilicate glass implementing low-power continuous (25 W) and pulsed (85 W, with an ultra-low duty cycle) DC magnetron sputtering. The characteristics of the resulting films were studied via atomic force microscopy (AFM), X-ray photoelectron spectroscopy (XPS), VIS spectroscopy, and four-point-probe measurements. Both deposition modes yield films with low surface roughness, and AFM analysis showed no topographical features indicative of columnar-and-void structures. The films exhibited high optical reflectivity and stable transmittance and reflectance across the visible spectrum. The electric resistivity could be measured even at single nanometer thickness, emphasizing the metallic character of the films and approaching the bulk titanium value at higher film thicknesses. The low power regime of magnetron sputter deposition not only offers the possibility of studying the development of physical characteristics during the growth of ultra-thin films but also provides the advantage of extremely low heat development and no evident mechanical stress on the substrate during the coating process. These results outline a path for low-power DC sputtering as a reliable approach for studying the evolution of functional properties in ultra-thin films and for the gentle fabrication of coatings where thermal stress must be avoided, making the method compatible with temperature-sensitive applications.

22 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TZTaraneh Sadat Zavvar
Taraneh Sadat Zavvar
GSGiulia Santo
Giulia Santo
LGLeonhard Gruber
Leonhard Gruber
AKAriane Kronthaler
Ariane Kronthaler
JHJudith Hagenbuchner
Judith Hagenbuchner
EGElisabeth Von Guggenberg
Elisabeth Von Guggenberg
Background/Objectives: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature and poor prognosis. Despite advances, relapse rates are high and effective therapies are limited. We previously demonstrated the diagnostic potential of the cholecystokinin-2 receptor (CCK2R)-targeting minigastrin analog [68Ga]Ga-DOTA-MGS5 in PET/CT imaging of different NETs. Building on this, we developed and evaluated [177Lu]Lu-DOTA-MGS5 as a therapeutic PRRT agent. Methods: Preclinical studies investigating the receptor-mediated cellular internalization and intracellular distribution over time in A431 cells with and without CCK2R expression were performed using the fluorescent tracer ATTO-488-MGS5. Short- and long-term cytotoxic effects of [177Lu]Lu-DOTA-MGS5 were evaluated on the same cell line using trypan blue exclusion and clonogenic survival assays. CCK2R expression was assessed by immunohistochemistry in 42 SCLC tissue specimens. In addition, the first PRRT with [177Lu]Lu-DOTA-MGS5 was conducted in a patient with extensive disease SCLC (ED-SCLC) after confirming CCK2R-positive uptake in [68Ga]Ga-DOTA-MGS5 PET/CT. Results: Rapid binding and internalization into A431-CCK2R cells, with progressive accumulation in intracellular compartments, was observed for ATTO-488-MGS5. Short-term irradiation effects of [177Lu]Lu-DOTA-MGS5 were comparable for 4 h and 24 h incubation and were between the effects obtained with 2 and 4 Gy of external beam radiotherapy (EBRT). Clonogenic survival of A431-CCK2R cells incubated with increasing activity of [177Lu]Lu-DOTA-MGS5 decreased in a dose-dependent manner. Immunohistochemistry on SCLC specimens confirmed moderate to high CCK2R expression in 16 out of 42 SCLC samples. In the first patient with SCLC treated with four cycles of [177Lu]Lu-DOTA-MGS5 with a total activity of 17.2 GBq, an improvement in clinical symptoms was observed. Conclusions: The preclinical and clinical results confirm the feasibility of [177Lu]Lu-DOTA-MGS5 PRRT in patients with SCLC and support further clinical studies investigating the therapeutic value and clinical applicability of this new CCK2R-targeted theranostic approach in larger patient cohorts.

6 June 2026 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
GSGiulia Santo
Giulia Santo
GSGianpaolo di Santo
Gianpaolo di Santo
AKAriane Kronthaler
Ariane Kronthaler
MFMohsen Farsad
Mohsen Farsad
LRLisa Maria Rossetti
Lisa Maria Rossetti
IVIrene Johanna Virgolini
Irene Johanna Virgolini
Background: Little is known about predictors of response to radionuclide therapy with PSMA-ligands in patients with [ 18 F]FDG-positive metastatic castration-resistant prostate cancer (mCRPC). We assessed the correlation between baseline characteristics, including dual tracer PET parameters, and response to [ 177 Lu]Lu-PSMA-I&T in a cohort of patients with [ 18 F]FDG-positive mCRPC. Prognostic factors related to progression-free survival (PFS) and overall survival (OS) were also investigated. Methods: mCRPC patients who underwent [ 68 Ga]Ga-PSMA-11 and [ 18 F]FDG PET/CT prior to [ 177 Lu]Lu-PSMA-I&T were retrospectively evaluated. Only [ 18 F]FDG-positive patients were included in the analysis. A semi-automatic segmentation tool was applied to measure the whole-body maximum standardized uptake value (SUV max ), mean standardized uptake value (SUV mean ), metabolic tumor volume (MTV), and total lesion uptake (TLU) on both PET/CTs. PSA response was defined as ≥ 30% and ≥ 50% decline. Imaging response, assessed two months after the last cycle, was defined according to RECIST 1.1 and/or PSMA PET progression (PPP) criteria. Clinical, biochemical, and imaging-based factors were correlated to response to treatment, PFS, and OS. Results: Twenty-five [ 18 F]FDG-positive patients who received [ 177 Lu]Lu-PSMA-I&T were included. PSA30 and PSA50 responses were achieved in 11/25 (44%) and in 9/25 (36%) patients, respectively. In the univariate analysis [ 68 Ga]Ga-PSMA-11 SUV mean ( p = 0.022) and [ 68 Ga]Ga-PSMA/[ 18 F]FDG SUV mean ratio ( p = 0.021) were significantly associated with PSA30 response. [ 68 Ga]Ga-PSMA-11 SUV mean was also significant in the multivariate model. ROC analysis indicated an optimal [ 68 Ga]Ga-PSMA-11 SUV mean cutoff value of 10.23 (AUC = 0.741), and a best discriminating [ 68 Ga]Ga-PSMA/[ 18 F]FDG SUV mean cutoff ratio of 2.08 (AUC = 0.727). In the univariate analysis for radiological PFS (rPFS), high ALP ( p = 0.023), [ 68 Ga]Ga-PSMA-11 MTV ( p = 0.011), [ 68 Ga]Ga-PSMA-11 TLU ( p = 0.015), and [ 18 F]FDG MTV ( p = 0.013) were significantly associated with shorter rPFS. [ 68 Ga]Ga-PSMA-11 MTV showed a borderline association with rPFS in the multivariate model ( p = 0.061). Hemoglobin levels ( p = 0.008), ALP ( p = 0.018) and PSA ( p = 0.023) values before treatment were associated with OS, as well as [ 68 Ga]Ga-PSMA-11 MTV ( p = 0.003), [ 68 Ga]Ga-PSMA-11 TLU ( p = 0.025), and [ 18 F]FDG MTV ( p = 0.024). However, no independent predictors of OS were identified in the multivariate analysis. Conclusions: Our preliminary results suggest that a whole-body [ 68 Ga]Ga-PSMA-11 SUV mean higher than 10 and a [ 68 Ga]Ga-PSMA-11/[ 18 F]FDG SUV mean ratio > 2 may serve as useful predictors for identifying patients likely to achieve at least a 30% reduction in PSA levels, even among [ 18 F]FDG-positive mCRPC patients. Furthermore, our findings support the prognostic significance of tumor burden either calculated by imaging-based volumetric parameters or by known biochemical markers of disease.

31 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
TZTaraneh Sadat Zavvar
Taraneh Sadat Zavvar
GSGiulia Santo
Giulia Santo
LGLeonhard Gruber
Leonhard Gruber
AKAriane Kronthaler
Ariane Kronthaler
JHJudith Hagenbuchner
Judith Hagenbuchner
EGElisabeth Von Guggenberg
Elisabeth Von Guggenberg
Rationale: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature and poor prognosis. Despite advances, relapse rates are high and effective therapies are limited. We previously demonstrated the diagnostic potential of the cholecystokinin-2 receptor-targeting minigastrin analog [ 68 Ga]Ga-DOTA-MGS5 in PET/CT imaging in different NETs. Building on this, we developed and evaluated [ 177 Lu]Lu-DOTA-MGS5 as a therapeutic PRRT agent. Methods: Preclinical studies investigating the cellular internalization and intracellular distribution over time in A431 cells were performed using the fluorescent tracer ATTO-488-MGS5. Short-and long-term cytotoxic effects of [ 177 Lu]Lu-DOTA-MGS5 were evaluated on the same cell line using trypan blue exclusion and clonogenic survival assays. CCK2R expression was assessed by immunohistochemistry in 42 SCLC tissue specimens. In addition, the first PRRT with [ 177 Lu]Lu-DOTA-MGS5 was conducted in a patient with extensive disease SCLC after confirming CCK2R-positive uptake in [ 68 Ga]Ga-DOTA-MGS5 PET/CT. Results: Rapid binding and internalization into A431-CCK2R cells, with progressive accumulation in intracellular compartments, was observed for ATTO-488-MGS5. Short-term irradiation effects of [ 177 Lu]Lu-DOTA-MGS5 were comparable for 4 h and 24 h incubation and lay between the effects obtained with 2 and 4 Gy of EBRT. Clonogenic survival of A431-CCK2R cells incubated with the increasing radioactivity of [ 177 Lu]Lu-DOTA-MGS5 decreased in a dose-dependent manner. Immunohistochemistry on SCLC specimens confirmed moderate to high CCK2R expression in 16 of 42 SCLC samples. In the first patient with SCLC treated with four cycles of [ 177 Lu]Lu-DOTA-MGS5 with a total activity of 17.2 GBq, no signs of toxicity were noticed. Conclusions: The preclinical and clinical results confirm the feasibility of [ 177 Lu]Lu-DOTA-MGS5 PRRT in patients with SCLC and support further clinical studies investigating the therapeutic value and clinical applicability of this new CCK2R-targeted theranostic approach in larger patient cohorts.